RNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the ...

A team from the Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER) has developed an innovative ...

Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with the National Institutes of Health estimating that more than ...

DNA nanostructures are exciting new biomedical tools with myriad potential in treatment, diagnosis and disease prevention.

Tuberculosis (TB) is one of the oldest and deadliest infectious diseases we know. It commonly impacts the lungs, but can also affect other areas of the body like the spine, brain or kidneys.

Nobel laureate David Baker’s latest foundation model can design proteins that interact to any biomolecule for broad biotech applications.

Cedars-Sinai scientists have created a new experimental drug called TY1 that helps the body repair damaged DNA and restore ...

Researchers created a highly efficient gene-editing method that fixes multiple DNA mutations in a single step. The breakthrough could revolutionize genetic medicine by making treatments for complex ...

Artificial untelligence (AI) stocks under $10 are publicly traded companies developing or applying AI technologies, with stock prices below $10 per share. These lower-priced AI stocks can present ...